KOKUA PHARMA INC. – Trademark Portfolio

Entity Type: 99

KOKUA PHARMA INC. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include REZQPUFF, PUFFADRENALN, and PUFFEPINEPHRIN. The owner is based in RICHMOND.

6091 GILBERT ROAD, SUITE 850

RICHMOND V7C5L9 , CA

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

KOKUA PHARMA INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (3 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does KOKUA PHARMA INC. have?

KOKUA PHARMA INC. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending.

What trademark classes does KOKUA PHARMA INC. file in?

KOKUA PHARMA INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are KOKUA PHARMA INC.'s most well-known trademarks?

KOKUA PHARMA INC.'s registered trademark portfolio includes well-known marks such as REZQPUFF, PUFFADRENALN, and PUFFEPINEPHRIN. These are among 3 currently registered trademarks in the portfolio.

What is KOKUA PHARMA INC.'s trademark registration success rate?

KOKUA PHARMA INC. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 1 application is pending review.